在免疫调节剂和生物制剂时代,炎症性肠病中更常实现激素节约——来自荷兰基于人群的IBDSL队列的结果
在基于人群的荷兰IBDSL队列中,共纳入2823例新诊断的克罗恩病(CD)或溃疡性结肠炎(UC)患者,比较不同诊断年代激素暴露与累积使用天数,并评估免疫调节剂和生物制剂的激素节约效应。结果显示激素暴露率保持稳定,CD长期累积激素使用逐渐减少,CD中使用免疫调节剂和生物制剂者需要激素的风险低于匹配对照。
要点
- 随时间推移,CD和UC的激素暴露率保持稳定(CD 54.0%,UC 31.4%)。
- CD长期累积激素使用逐渐减少,UC初始下降后趋于稳定。
- 仅在CD中,免疫调节剂和生物制剂使用者需要激素的风险低于匹配对照。
核心结论
- 在真实世界环境中,较近期诊断的IBD患者在病程第二年起使用较少量的激素。
- 在CD中,发现使用免疫调节剂和生物制剂与激素节约存在显著关联。
- 这些结论支持越来越多地使用这些治疗方式。
研究设计与样本
- 基于人群的炎症性肠病南林堡(IBDSL)队列研究,共纳入2823例新诊断的克罗恩病(CD)或溃疡性结肠炎(UC)患者。
- 按诊断年代分为1991-1998年(CD:n=316,UC:n=539)、1999-2005年(CD:n=387,UC:n=527)和2006-2011年(CD:n=459,UC:n=595)三组。
- 比较各组间激素暴露和累积使用天数,并评估免疫调节剂和生物制剂的激素节约效应。
主要发现
- 随时间推移,激素暴露率保持稳定(CD为54.0%,UC为31.4%)。
- 疾病第一年累积激素使用:CD为83天(四分位距(IQR)35-189),UC为62天(IQR 0-137)。
- 长期累积激素使用在CD中逐渐减少(1991-1998年代:366天(IQR 107-841),2006-2011年代:120天(IQR 72-211),P<0.01)。
- 在UC中观察到初始下降(1991-1998年代:184天(IQR 86-443),1999-2005年代:166天(IQR 74-281),P=0.03),此后趋于稳定。
- 仅在CD中,免疫调节剂使用者需要激素的风险低于匹配对照(33.6% vs. 49.9%,P<0.01),生物制剂使用者需要激素的风险也低于匹配对照(25.7% vs. 38.2%,P=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Corticosteroid-free remission is an emerging treatment goal in the management of inflammatory bowel disease (IBD). In the population-based Inflammatory Bowel Disease South Limburg cohort, we studied temporal changes in corticosteroid use and assessed the corticosteroid-sparing effects of immunomodulators and biologicals in real life. METHODS: In total, 2,823 newly diagnosed patients with Crohn's disease (CD) or ulcerative colitis (UC) were included. Corticosteroid exposure and cumulative days of use were compared between patients diagnosed in 1991-1998 (CD: n=316, UC: n=539), 1999-2005 (CD: n=387, UC: n=527), and 2006-2011 (CD: n=459, UC: n=595). Second, the corticosteroid-sparing effects of immunomodulators and biologicals were assessed. RESULTS: Over time, the corticosteroid exposure rate was stable (54.0% in CD and 31.4% in UC), even as the cumulative corticosteroid use in the first disease year (CD: 83 days (interquartile range (IQR) 35-189), UC: 62 days (IQR 0-137)). On the long-term, a gradual decrease in cumulative corticosteroid use was seen in CD (era '91-'98: 366 days (IQR 107-841), era '06-'11: 120 days (IQR 72-211), P<0.01), whereas in UC an initial decrease was observed (era '91-'98: 184 days (IQR 86-443), era '99-'05: 166 days (IQR 74-281), P=0.03), and stabilization thereafter. Immunomodulator and biological users had a lower risk of requiring corticosteroids than matched controls in CD only (33.6% vs. 49.9%, P<0.01, and 25.7% vs. 38.2%, P=0.04, respectively). CONCLUSIONS: In a real-world setting, more recently diagnosed IBD patients used lower amounts of corticosteroids as of the second year of disease. For CD, a significant association was found with the use of immunomodulators and biologicals. These conclusions support the increasing use of these treatment modalities.
引用
- Jeuring SFG, Biemans VBC, van den Heuvel TRA, et al. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort. Am J Gastroenterol. 2018. PMID: 29317770. doi:10.1038/ajg.2017.482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。